@sarahkliff Classic: innovation largely constrained by R&D model, not financial rewards: http://www.nature.com/nrd/journal/v8/n12/full/nrd2961.html …
-
-
- End of conversation
New conversation -
-
-
@sarahkliff I can forward a few relevant unpublished papers, by email. -
@jamie_love thanks! It's sarah@vox.com
End of conversation
New conversation -
-
- End of conversation
New conversation -
-
@sarahkliff Acemoglu and Linn Quarterly Journal of Economics, 2004 -
@aschwattie Awesome thanks!
End of conversation
New conversation -
-
-
@sarahkliff This should be good background. Useful references. It's on effect of market size on pharma innovation http://economics.mit.edu/files/4464 -
@sarahkliff Great job btw moderating Casey Mulligan and Peter Orszag at the#ASHEcon14!
End of conversation
New conversation -
-
-
@sarahkliff@RANDCorporation discusses PRIZE model here: http://www.rand.org/pubs/research_reports/RR308.html … & in older reports; also@jamie_love http://www.keionline.org/node/1147 -
@sophiekasimow@sarahkliff A policy which was also introduced as a bill by Sen. Sanders a few years ago: http://www.raps.org/regulatoryDetail.aspx?id=6776 …
End of conversation
New conversation -
-
- 1 more reply
New conversation -
-
@sarahkliff try searching for Joel Lexchin or@cmrherder - 1 more reply
New conversation -
-
-
@sarahkliff Also Grabowski’s net present value model; provides analysis on data exclusivity incentives for biologics. http://www.nature.com/nrd/journal/v10/n1/full/nrd3277.html …Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@sarahkliff Deloitte Uncertainties paper- uncertainty associated w/ biopharm R&D and impact on returns, available:http://tinyurl.com/ofk5kptThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.